Production (Stage)
Evofem Biosciences, Inc.
EVFM
$0.0098
$0.00022.08%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.70% | 6.28% | 26.09% | 19.54% | -12.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.70% | 6.28% | 26.09% | 19.54% | -12.95% |
| Cost of Revenue | -39.60% | -41.12% | -44.87% | -25.07% | 23.17% |
| Gross Profit | 28.43% | 32.66% | 81.44% | 47.68% | -25.44% |
| SG&A Expenses | 7.36% | -1.39% | -32.31% | -49.59% | -57.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.27% | -25.03% | -32.26% | -48.90% | -57.08% |
| Operating Income | 73.67% | 56.99% | 62.09% | 73.22% | 70.89% |
| Income Before Tax | -106.12% | -116.72% | -116.97% | -13.99% | 207.25% |
| Income Tax Expenses | -100.00% | -100.00% | -100.00% | -29.63% | -68.18% |
| Earnings from Continuing Operations | -106.13% | -116.72% | -116.97% | -13.98% | 207.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.13% | -116.72% | -116.97% | -13.98% | 207.12% |
| EBIT | 73.67% | 56.99% | 62.09% | 73.22% | 70.89% |
| EBITDA | 78.43% | 59.55% | 62.40% | 72.81% | 70.81% |
| EPS Basic | -100.27% | -102.41% | 86.71% | -87.02% | 102.12% |
| Normalized Basic EPS | 99.71% | 97.71% | 98.01% | -101.63% | 98.09% |
| EPS Diluted | 99.10% | 97.27% | 95.43% | 96.77% | 98.95% |
| Normalized Diluted EPS | 99.13% | 96.77% | 97.63% | -104.21% | 98.97% |
| Average Basic Shares Outstanding | 685.71% | 1,501.71% | 2,482.24% | 2,485.51% | 1,498.39% |
| Average Diluted Shares Outstanding | 914.43% | 148.11% | 138.92% | 29,052.68% | 11,243.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |